JOHN CHARLES ARAUJO to Bone Neoplasms
This is a "connection" page, showing publications JOHN CHARLES ARAUJO has written about Bone Neoplasms.
Connection Strength
0.784
-
Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Clin Nucl Med. 2016 Apr; 41(4):268-73.
Score: 0.217
-
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther. 2009 Nov; 8(22):2153-9.
Score: 0.140
-
Targeting Src signaling in metastatic bone disease. Int J Cancer. 2009 Jan 01; 124(1):1-6.
Score: 0.132
-
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol. 2020 02; 3(1):119-127.
Score: 0.067
-
Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med. 2015 Oct; 56(10):1507-12.
Score: 0.052
-
Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med. 2015 Aug; 56(8):1177-84.
Score: 0.051
-
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 01; 121(1):69-76.
Score: 0.049
-
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012 Jan 01; 118(1):63-71.
Score: 0.039
-
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 05 10; 34(14):1652-9.
Score: 0.014
-
Src signaling pathways in prostate cancer. Cancer Metastasis Rev. 2014 Sep; 33(2-3):595-606.
Score: 0.012
-
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4.
Score: 0.011